Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 85
Filter
1.
Cardiovasc Toxicol ; 19(3): 229-236, 2019 06.
Article in English | MEDLINE | ID: mdl-30377924

ABSTRACT

The abuse of new psychoactive substances (NPS) is an emerging social problem. Methoxetamine, one of the NPS, was designed as an alternative to ketamine and it was considered an NPS candidate owing to its high addictive potential. However, cardiotoxicity of the phencyclidine analogue, methoxetamine, has not been extensively evaluated. P21 protein (Cdc42/Rac)-activated kinase 1 (PAK-1) is associated with the drug-induced cardiotoxicity and hypertrophy of cardiomyocytes. In the present study, we investigated the effects of methoxetamine on rat cardiomyocytes and PAK-1. Methoxetamine (at 10 µM) reduced cell viability and PAK-1 mRNA levels in H9c2 cells. Methoxetamine treatment (100 µM) decreased the beating rate of primary cardiomyocytes. However, 100 µM methoxetamine-induced heart rate decline was less than 100 µM PCP- or ketamine-induced heart rate decline. Meanwhile, fingolimod hydrochloride (FTY720, 1 µM), a PAK-1 activator, increased cell viability and inhibited hypertrophy induced by methoxetamine in H9c2 cells. These results suggest that methoxetamine may have harmful effects on the cardiovascular system through the regulation of the expression and function of PAK-1.


Subject(s)
Cyclohexanones/toxicity , Cyclohexylamines/toxicity , Illicit Drugs/toxicity , Myocytes, Cardiac/drug effects , p21-Activated Kinases/metabolism , Animals , Cardiotoxicity , Cell Size/drug effects , Cell Survival/drug effects , ERG1 Potassium Channel/drug effects , ERG1 Potassium Channel/metabolism , Heart Rate/drug effects , Hep G2 Cells , Humans , Mice, Inbred ICR , Myocytes, Cardiac/enzymology , Myocytes, Cardiac/pathology , Rats , Signal Transduction/drug effects
2.
Bioorg Med Chem ; 27(1): 161-166, 2019 01 01.
Article in English | MEDLINE | ID: mdl-30503782

ABSTRACT

Inspite of progress made for the discovery of novel antiepileptic drugs, epilepsy remains an unmet medical need. We synthesized nine trifluoromethylated enaminone derivatives and tested them for their anticonvulsant activity using maximal electroshock seizure (MES) test, subcutaneous pentylenetetrazole (scPTZ) test, and rotorod test for neurotoxicity. Among the compounds tested 3-(4-fluoro-3-(trifluomethyl)benzylamino)-5-(trifluoromethyl)cyclohex-2-enone (4f) showed ED50 of 23.47 mg/kg, when given orally to rats, 3-(4-chlorophenylamino)-5-(trifluoromethyl)cyclohex-2-enone (5a), which was previously reported by us but for which no quantitative data was available at the time, exhibited an ED50 of 62.39 mg/kg. Under the same conditions commercially available carbamazepine showed an ED50 of 28.20 mg/kg. There were no neurotoxicity observed upto a dose of 300 mg/kg for all the tested compounds. Compounds 4f and 5a represent good lead compounds for further development.


Subject(s)
Anticonvulsants/pharmacology , Benzylamines/pharmacology , Cyclohexanones/pharmacology , Cyclohexylamines/pharmacology , Hydrocarbons, Fluorinated/pharmacology , Seizures/prevention & control , Animals , Anticonvulsants/chemical synthesis , Anticonvulsants/pharmacokinetics , Anticonvulsants/toxicity , Benzylamines/chemical synthesis , Benzylamines/pharmacokinetics , Benzylamines/toxicity , Computer Simulation , Cyclohexanones/chemical synthesis , Cyclohexanones/pharmacokinetics , Cyclohexanones/toxicity , Cyclohexylamines/chemical synthesis , Cyclohexylamines/pharmacokinetics , Cyclohexylamines/toxicity , Drug Design , Hydrocarbons, Fluorinated/chemical synthesis , Hydrocarbons, Fluorinated/pharmacokinetics , Hydrocarbons, Fluorinated/toxicity , Male , Mice , Molecular Structure , Rats , Structure-Activity Relationship
3.
Am J Physiol Heart Circ Physiol ; 314(3): H659-H668, 2018 03 01.
Article in English | MEDLINE | ID: mdl-29127238

ABSTRACT

Clinical studies have suggested that myocardial iron is a risk factor for left ventricular remodeling in patients after myocardial infarction. Ferroptosis has recently been reported as a mechanism of iron-dependent nonapoptotic cell death. However, ferroptosis in the heart is not well understood. Mechanistic target of rapamycin (mTOR) protects the heart against pathological stimuli such as ischemia. To define the role of cardiac mTOR on cell survival in iron-mediated cell death, we examined cardiomyocyte (CM) cell viability under excess iron and ferroptosis conditions. Adult mouse CMs were isolated from cardiac-specific mTOR transgenic mice, cardiac-specific mTOR knockout mice, or control mice. CMs were treated with ferric iron [Fe(III)]-citrate, erastin, a class 1 ferroptosis inducer, or Ras-selective lethal 3 (RSL3), a class 2 ferroptosis inducer. Live/dead cell viability assays revealed that Fe(III)-citrate, erastin, and RSL3 induced cell death. Cotreatment with ferrostatin-1, a ferroptosis inhibitor, inhibited cell death in all conditions. mTOR overexpression suppressed Fe(III)-citrate, erastin, and RSL3-induced cell death, whereas mTOR deletion exaggerated cell death in these conditions. 2',7'-Dichlorodihydrofluorescein diacetate measurement of reactive oxygen species (ROS) production showed that erastin-induced ROS production was significantly lower in mTOR transgenic versus control CMs. These findings suggest that ferroptosis is a significant type of cell death in CMs and that mTOR plays an important role in protecting CMs against excess iron and ferroptosis, at least in part, by regulating ROS production. Understanding the effects of mTOR in preventing iron-mediated cell death will provide a new therapy for patients with myocardial infarction. NEW & NOTEWORTHY Ferroptosis has recently been reported as a new form of iron-dependent nonapoptotic cell death. However, ferroptosis in the heart is not well characterized. Using cultured adult mouse cardiomyocytes, we demonstrated that the mechanistic target of rapamycin plays an important role in protecting cardiomyocytes against excess iron and ferroptosis.


Subject(s)
Iron/metabolism , Myocardial Reperfusion Injury/prevention & control , Myocytes, Cardiac/enzymology , TOR Serine-Threonine Kinases/metabolism , Animals , Carbolines/toxicity , Cell Death , Cell Survival , Cells, Cultured , Cyclohexylamines/toxicity , Ferric Compounds/toxicity , Male , Mice, Inbred C57BL , Mice, Transgenic , Myocardial Reperfusion Injury/enzymology , Myocardial Reperfusion Injury/pathology , Myocytes, Cardiac/drug effects , Myocytes, Cardiac/pathology , Phenylenediamines/toxicity , Piperazines/toxicity , Reactive Oxygen Species/metabolism , Signal Transduction , TOR Serine-Threonine Kinases/genetics
4.
Regul Toxicol Pharmacol ; 85: 25-32, 2017 Apr.
Article in English | MEDLINE | ID: mdl-28159477

ABSTRACT

In the EU, chemicals with a production or import volume in quantities of one metric ton per year or more have to be tested for skin sensitizing properties under the REACH regulation. The murine Local Lymph Node Assay (LLNA) and its modifications are widely used to fulfil the data requirement, as it is currently considered the first-choice method for in vivo testing to cover this endpoint. This manuscript describes a case study highlighting the importance of understanding the chemistry of the test material during testing for 'skin sensitization' of MCDA (mixture of 2,4- and 2,6-diamino-methylcyclohexane) with particular focus on the vehicle used. While the BrdU-ELISA modification of the LLNA using acetone/olive oil (AOO) as vehicle revealed expectable positive results. However, the concentration control analysis unexpectedly revealed an instability of MCDA in the vehicle AOO. Further studies on the reactivity showed MCDA to rapidly react with AOO under formation of various imine structures, which might have caused the positive LLNA result. The repetition of the LLNA using propylene glycol (PG) as vehicle did not confirm the positive results of the LLNA using AOO. Finally, a classification of MCDA as skin sensitizer according to the Globally Harmonized System (GHS) was not justified.


Subject(s)
Allergens , Cyclohexylamines , Excipients/chemistry , Haptens , Acetone/chemistry , Allergens/chemistry , Allergens/classification , Allergens/toxicity , Animals , Cyclohexylamines/chemistry , Cyclohexylamines/classification , Cyclohexylamines/toxicity , Dermatitis, Allergic Contact , Female , Haptens/chemistry , Haptens/classification , Haptens/toxicity , Local Lymph Node Assay , Mice, Inbred CBA , Olive Oil/chemistry , Propylene Glycol/chemistry , Sensitivity and Specificity
5.
Int J Mol Sci ; 18(1)2017 Jan 18.
Article in English | MEDLINE | ID: mdl-28106785

ABSTRACT

The novel synthetic psychoactive ketamine analog methoxetamine is reportedly being used for recreational purposes. As ketamine use can result in urinary dysfunction, we conducted the present study to investigate how methoxetamine affects the bladder. A cystometry investigation showed that female Sprague-Dawley rats experienced increased micturition frequency bladder dysfunction after receiving a daily intraperitoneal injection of 30 mg/kg methoxetamine or ketamine for periods of 4 or 12 weeks. Histologic examinations of rat bladder tissue revealed damaged urothelium barriers, as well as evidence of inflammatory cell infiltration and matrix deposition. The drug-treated rats showed significantly upregulated levels of pro-inflammatory cytokines such as IL-1ß, IL-6, CCL-2, CXCL-1, CXCL-10, NGF, and COX-2. In addition, interstitial fibrosis was confirmed by increased levels of collagen I, collagen III, fibronectin and TGF-ß. Besides direct toxic effect on human urothelial cells, methoxetaminealso induced the upregulation related cytokines. Our results indicate that long term methoxetamine treatment can induce bladder dysfunction and inflammation in rats. Methoxetamine was confirmed to produce direct toxic and pro-inflammatory effects on human urothelial cells. Methoxetamine-associated bladder impairment may be similar to ketamine-induced cystitis.


Subject(s)
Cyclohexanones/toxicity , Cyclohexylamines/toxicity , Inflammation/pathology , Ketamine/analogs & derivatives , Urinary Bladder/pathology , Urinary Bladder/physiopathology , Animals , Body Weight/drug effects , Cell Line , Chemokines/genetics , Chemokines/metabolism , Epithelial Cells/drug effects , Epithelial Cells/metabolism , Epithelial Cells/pathology , Epithelium/drug effects , Epithelium/pathology , Extracellular Matrix/drug effects , Extracellular Matrix/metabolism , Female , Gene Expression Regulation/drug effects , Inflammation Mediators/metabolism , Macrophages/drug effects , Macrophages/metabolism , Mast Cells/drug effects , Mast Cells/pathology , Mucous Membrane/drug effects , Mucous Membrane/pathology , Rats , Rats, Sprague-Dawley , Up-Regulation/drug effects , Urinary Bladder/drug effects , Urination/drug effects , Urodynamics/drug effects
6.
Drug Alcohol Rev ; 35(2): 212-7, 2016 Mar.
Article in English | MEDLINE | ID: mdl-25867295

ABSTRACT

INTRODUCTION AND AIMS: To assess the prevalence of use and subjective effect profile of methoxetamine among a group of polydrug users. DESIGN AND METHODS: Cross-sectional, anonymous, online survey of UK-based polydrug users was conducted. Prevalence of lifetime, last year and last month use, sourcing of the drugs, motivations for use, and subjective effect and risk profile compared with that of ketamine were measured. RESULTS: There were 7700 UK-based polydrug users, of whom 326 reported recent use of methoxetamine. Of the whole sample, 4.2% reported last 12 month use of methoxetamine compared with 24.5% for ketamine. The most common route of use was intranasal and the predominate effect described as psychedelic. Of the 15.5% of last year users of ketamine reporting last year use of methoxetamine, only 18.7% reported that they thought methoxetamine was less damaging to their kidneys or bladder than ketamine. Its broad effect profile, based on participants' first experience of use, was very similar to that of ketamine. Almost one-third of users reported that they did not intend to try the drug again. DISCUSSION AND CONCLUSIONS: Methoxetamine appears to have a broadly similar effect profile to that of ketamine. Only a minority of participants were motivated to use it because they believed it was less damaging to their kidneys or bladder than ketamine. The impact of the recent temporary banning order on availability and use of both methoxetamine and ketamine should be monitored carefully.


Subject(s)
Cyclohexanones/administration & dosage , Cyclohexylamines/administration & dosage , Hallucinogens/administration & dosage , Illicit Drugs , Substance-Related Disorders/epidemiology , Adult , Cross-Sectional Studies , Cyclohexanones/pharmacology , Cyclohexanones/toxicity , Cyclohexylamines/pharmacology , Cyclohexylamines/toxicity , Female , Hallucinogens/pharmacology , Hallucinogens/toxicity , Humans , Illicit Drugs/pharmacology , Illicit Drugs/toxicity , Ketamine/administration & dosage , Ketamine/pharmacology , Ketamine/toxicity , Male , Motivation , Prevalence , Surveys and Questionnaires , United Kingdom/epidemiology , Young Adult
7.
Hum Psychopharmacol ; 30(4): 244-8, 2015 Jul.
Article in English | MEDLINE | ID: mdl-26216557

ABSTRACT

OBJECTIVE: The goal of this study is to provide an update on the data given on methoxetamine (MXE)-related fatalities that occurred in 2011-2013, presented at the Second International Conference on Novel Psychoactive Substances. METHODS: Fatalities involving MXE were extracted from the database of the National Programme on Substance Abuse Deaths, which receives information on drug-related deaths from Coroners in the UK and Islands (Isle of Man, Jersey, Guernsey) and other data suppliers. RESULTS: Eight cases, received by 3 September 2013, in which MXE was found at post-mortem and/or directly implicated in the death and/or mentioned in the Coroner's verdict are described. The median age at death was 27 years, with the majority of White ethnicity (6/8) and male (7/8). MXE was used together with other substances in 7/8 cases. MXE was found at post-mortem in all cases, directly implicated in the deaths of four and likely to have had an influence in two. CONCLUSIONS: More research needs to be conducted into its health effects and toxicity potential. Health care professionals should be made aware of the potential health harms of MXE, in order to develop early intervention measures and minimise the number of MXE-related poisonings and fatalities.


Subject(s)
Cyclohexanones/toxicity , Cyclohexylamines/toxicity , Illicit Drugs/toxicity , Substance-Related Disorders/mortality , Adolescent , Adult , Diagnosis , Female , Humans , Male , Retrospective Studies , United Kingdom , Young Adult
9.
Mil Med ; 179(10): 1149-57, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25269134

ABSTRACT

Recent years have seen the emergence and proliferation of "legal highs" or "designer drugs," compounds purposefully designed as legal alternatives to controlled substances of abuse. This article describes methoxetamine, a dissociative drug belonging to the arylcyclohexylamine class including phencyclidine and ketamine. Methoxetamine acts principally on the glutamatergic N-methyl-D-aspartate receptor and the serotonin receptor. It is sold as a white or off-white powder. Marketed as a "bladder friendly" alternative to ketamine, preliminary research suggests renal and cystic toxicity similar to ketamine. Methoxetamine is primarily ingested nasally, though also orally, intramuscularly, intravenously, and rectally. Users report dissociative features and, at higher doses, an "m-hole" experience akin to ketamine's "k-hole" described as extreme depersonalization and derealization. The 13 cases of acute methoxetamine toxicity described in the literature are summarized. The toxidrome consists of dissociation/delirium, sympathetic activation, and cerebellar symptoms. Methoxetamine is not detected in standard urine drug tests and there are no reliable laboratory findings. Management of acute methoxetamine toxicity is supportive, consisting of benzodiazepines, antiemetics, intravenous fluids, and respiratory support as indicated. Should methoxetamine conform to the observed 2-year lag of designer drugs migrating from Europe to the United States usage may increase in early 2014.


Subject(s)
Cyclohexanones/toxicity , Cyclohexylamines/toxicity , Designer Drugs/toxicity , Illicit Drugs/toxicity , Military Personnel , Humans , Substance-Related Disorders/diagnosis , Substance-Related Disorders/therapy , United States
10.
Toxicol Lett ; 230(3): 402-7, 2014 Nov 04.
Article in English | MEDLINE | ID: mdl-25128700

ABSTRACT

Methoxetamine is one of the constantly growing group of novel psychoactive substances that has emerged in recent years. The compound belongs to the arylcyclohexylamine class, which is used for its recreational and psychedelic effects. Methoxetamine is a structural analogue of ketamine, with a much longer duration of action and intensity of effects, and has been extensively advertised as its 'legal' and 'bladder friendly' alternative. This review surveys the current state of knowledge regarding the metabolism, pharmacology, prevalence and pattern of methoxetamine use, and analytical methods of its detection. Consumption of methoxetamine bears a significant health risk and may even lead to fatal intoxication. A significant amount of research is still needed in order to fully quantify the short- and long-term effects of methoxetamine and its interaction with other drugs of abuse.


Subject(s)
Cyclohexanones/toxicity , Cyclohexylamines/toxicity , Hallucinogens/toxicity , Illicit Drugs/toxicity , Cyclohexanones/administration & dosage , Cyclohexanones/chemistry , Cyclohexylamines/administration & dosage , Cyclohexylamines/chemistry , Hallucinogens/administration & dosage , Humans , Illicit Drugs/adverse effects , Ketamine/chemistry , Ketamine/toxicity , Substance-Related Disorders/etiology
11.
J Anal Toxicol ; 38(7): 410-5, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24904014

ABSTRACT

Methoxetamine (MXE) is increasingly used and abused, as it is frequently presented as being safer than ketamine, and legal. Cases of only MXE consumption being associated with the occurrence of seizures are rarely reported. A single MXE intoxication case by inhalation is described concerning a 21-year-old man, not known to be epileptic, who was found collapsed in his bedroom, supposedly after an epileptic seizure. He was transferred to the Emergency Department of the Henri Mondor Hospital, Aurillac, France. He was conscious, but with a sinus bradycardia (48/min) and an ST-segment elevation on the electrocardiogram, and a slightly increased creatine kinase level (270 U/L) and hyponatremia (127 mmol/L). New seizure activity occurred during hospitalization, but the clinical course in the intensive care unit was favorable. Quantitation of MXE in serum and urine using gas chromatography coupled to mass spectrometry (GC-MS) was developed, as well as a liquid chromatography coupled to tandem mass spectrometry (LC-MS-MS) method for the determination of MXE in hair. Limits of detection and quantification were, respectively, 2 and 10 µg/L for the GC-MS method and both 0.5 pg/mg for the LC-MS-MS method. Concentrations of 30 and 408 µg/L were, respectively, measured in serum and urine. Concentrations of 135 and 145 pg/mg were detected in two 2.5 cm hair strands, consistent with one or several consumptions during the 2 ½ months prior to sampling. A sample of the powder consumed was available and also analyzed. This case illustrates the dangers of this drug, which justify its classification as a narcotic in France since August 2013.


Subject(s)
Cyclohexanones/analysis , Cyclohexanones/toxicity , Cyclohexylamines/analysis , Cyclohexylamines/toxicity , Illicit Drugs/analysis , Illicit Drugs/toxicity , Seizures/chemically induced , Substance Abuse Detection/methods , Cyclohexanones/blood , Cyclohexanones/urine , Cyclohexylamines/blood , Cyclohexylamines/urine , Gas Chromatography-Mass Spectrometry , Hair/chemistry , Humans , Illicit Drugs/blood , Illicit Drugs/urine , Inhalation Exposure , Limit of Detection , Male , Reproducibility of Results , Seizures/diagnosis , Spectrometry, Mass, Electrospray Ionization , Young Adult
12.
Clin Toxicol (Phila) ; 52(3): 176-80, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24580056

ABSTRACT

UNLABELLED: CONTEXT.: Methoxetamine is a ketamine analogue that has recently emerged as a novel psychoactive substance. Chronic ketamine use is associated with significant bladder and renal toxicity. Methoxetamine has been marketed as "bladder friendly", but there is no data to be able to substantiate this claim. OBJECTIVE: To characterise the patterns of bladder and renal toxicity associated with 3 months of methoxetamine administration in an animal model. MATERIALS AND METHODS: Two-month-old Institute of Cancer Research mice were administered 30 mg/kg methoxetamine intraperitoneally (n = 5) or saline (n = 3 control) for 3 months. The animals were then sacrificed and histological examination, immuno-cytochemistry using polyclonal anti-CD4 antibodies and sirius-red staining for collagen were performed. RESULTS: The kidneys of methoxetamine-treated animals showed inflammatory cell infiltration, tubular cell necrosis and glomerular damage (1.9 ± 0.3% shrunken glomeruli in control, 9.8 ± 0.8% in methoxetamine-treated mice (p < 0.0001); 2.9 ± 0.3% tubular cell degeneration in control, 20.4 ± 1.1% in methoxetamine-treated mice (p < 0.0001)). There was a greater density of mononuclear cells in the bladder lamina propria and submucosa in methoxetamine-treated mice (43.0 ± 2.1 per 250 × 250 µm) than controls (7.1 ± 1.2 per 250 × 250 µm), p < 0.001. CD4-positive staining was seen in the bladder submucosa and lamina propria of all methoxetamine-treated mice and muscle-layer of two methoxetamine-treated mice; these changes were not seen in the control mice. There was an increase in sirius-red collagen in the bladder sub-mucosa and muscle-layer in the methoxetamine-treated mice compared with control mice. DISCUSSION: This study has shown that 3 months of daily 30 mg/kg intra-peritoneal methoxetamine results in significant bladder and renal toxicity in mice. Changes in the bladder included inflammatory changes with subsequent fibrosis and changes in the kidney were seen at both a tubular and glomerular level. These changes are similar to those seen in comparable animal models of chronic ketamine administration. Further work is required to determine the time course of the onset of these effects and whether the effects are reversible with methoxetamine cessation.


Subject(s)
Cyclohexanones/toxicity , Cyclohexylamines/toxicity , Kidney/drug effects , Urinary Bladder/drug effects , Animals , Kidney/pathology , Male , Mice , Mice, Inbred ICR , Time Factors , Urinary Bladder/pathology
13.
Emerg Med J ; 31(1): 45-7, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23349353

ABSTRACT

OBJECTIVE: To report the demographic and clinical characteristics of cases of methoxetamine toxicity reported to The National Poisons Information Service (NPIS) by healthcare professionals. To assess the pattern of enquiries from health professionals to the UK NPIS related to methoxetamine, including the period of the making of the UK first Temporary Class Drug Order (TCDO). METHODS: All telephone enquiries to and user sessions for TOXBASE, the NPIS on-line information resource, related to methoxetamine (and synonyms 'MXE', 'mket' and '2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone') were reviewed from 1 April 2010 to 1 August 2012. Data were compared for the 3 months before and after the TCDO. RESULTS: There were 47 telephone enquiries and 298 TOXBASE sessions regarding methoxetamine during the period of study. Comparing the 3 months before and after the TCDO, TOXBASE sessions for methoxetamine fell by 79% (from 151 to 32) and telephone enquiries by 80% (from 15 to 3). Clinical features reported by enquirers were consistent with case reports of analytically confirmed methoxetamine toxicity and typical toxidromes were of stimulant (36%), reduced consciousness (17%), dissociative (11%) and cerebellar (6.4%) types, but also particularly featured acute disturbances in mental heath (43%). CONCLUSIONS: Structured NPIS data may reveal trends in drugs of abuse use and toxicity when interpreted within their limitations. Since April 2012, there have been fewer enquiries to NPIS from clinicians, indicating reduced presentations with suspected methoxetamine toxicity to healthcare services. It is unclear if this is related to the TCDO made on 5 April 2012.


Subject(s)
Cyclohexanones/toxicity , Cyclohexylamines/toxicity , Cyclohexanones/classification , Cyclohexylamines/classification , Databases, Factual , Drug Information Services , Substance-Related Disorders/epidemiology , Telephone , United Kingdom
15.
Anal Bioanal Chem ; 405(19): 6307-21, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23774830

ABSTRACT

Methoxetamine (MXE; 2-(3-methoxyphenyl)-2-(N-ethylamino)-cyclohexanone), a ketamine analog, is a new designer drug and synthesized for its longer lasting and favorable pharmacological effects over ketamine. The aims of the presented study were to identify the phases I and II metabolites of MXE in rat and human urine by GC-MS and LC-high-resolution (HR)-MS(n) and to evaluate their detectability by GC-MS and LC-MS(n) using authors' standard urine screening approaches (SUSAs). Furthermore, human cytochrome P450 (CYP) enzymes were identified to be involved in the initial metabolic steps of MXE in vitro, and respective enzyme kinetic studies using the metabolite formation and substrate depletion approach were conducted. Finally, human urine samples from forensic cases, where the ingestion of MXE was suspected, were analyzed. Eight metabolites were identified in rat and different human urines allowing postulation of the following metabolic pathways: N-deethylation, O-demethylation, hydroxylation, and combinations as well as glucuronidation or sulfation. The enzyme kinetic studies showed that the initial metabolic step in humans, the N-deethylation, was catalyzed by CYP2B6 and CYP3A4. Both SUSAs using GC-MS or LC-MS(n) allowed monitoring an MXE intake in urine.


Subject(s)
Chromatography, Liquid/methods , Cyclohexanones/pharmacokinetics , Cyclohexylamines/pharmacokinetics , Cytochrome P-450 Enzyme System/metabolism , Designer Drugs/pharmacokinetics , Gas Chromatography-Mass Spectrometry/methods , Inactivation, Metabolic , Ketamine/analogs & derivatives , Animals , Cyclohexanones/toxicity , Cyclohexanones/urine , Cyclohexylamines/toxicity , Cyclohexylamines/urine , Cytochrome P-450 Enzyme System/chemistry , Designer Drugs/toxicity , Humans , Kinetics , Male , Rats , Rats, Wistar
16.
Ther Drug Monit ; 34(4): 363-7, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22673201

ABSTRACT

Since the turn of the 21st century, there has been an increase in the availability and use of novel psychoactive substances (also known as "legal highs") across Europe. Currently, there is limited information available on the potential acute toxicity (harms) associated with the use of these novel psychoactive substances. There are a number of potential data sources that can provide information on the acute toxicity associated with their use: (1) user reports on Internet discussion fora; (2) subpopulation level surveys of self-reported harms/unwanted effects (3) regional or national poisons information service accesses for support on presentations to healthcare facilities relating to acute toxicity; (4) case reports/series based on self-reported use or analytically confirmed use; and (5) human volunteer studies assessing potential acute toxicological effects. Each of these data sources has its own limitations, particularly those that are based on self-reported use because there are a number of European studies that show that there is inconsistency in the substance(s) in the "drug" that an individual uses. However, by using a multilayered approach of combining different sources, it is possible to reduce the overall impact of the limitations of any one individual data source. In this review article, we will combine information from these different data sources to describe the pattern of acute toxicity associated with 4 novel psychoactive substances: 1-benzylpiperazine, mephedrone (4-methylmethcathinone), synthetic cannabinoid receptor agonists, and methoxetamine.


Subject(s)
Psychotropic Drugs/adverse effects , Psychotropic Drugs/toxicity , Animals , Cannabinoid Receptor Antagonists/adverse effects , Cannabinoid Receptor Antagonists/toxicity , Cyclohexanones/adverse effects , Cyclohexanones/toxicity , Cyclohexylamines/adverse effects , Cyclohexylamines/toxicity , Europe , Humans , Methamphetamine/adverse effects , Methamphetamine/analogs & derivatives , Methamphetamine/toxicity , Piperazines/adverse effects , Piperazines/toxicity
17.
J Med Toxicol ; 8(1): 15-32, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22271566

ABSTRACT

Despite their widespread Internet availability and use, many of the new drugs of abuse remain unfamiliar to health care providers. The herbal marijuana alternatives, like K2 or Spice, are a group of herbal blends that contain a mixture of plant matter in addition to chemical grade synthetic cannabinoids. The synthetic cathinones, commonly called "bath salts," have resulted in nationwide emergency department visits for severe agitation, sympathomimetic toxicity, and death. Kratom, a plant product derived from Mitragyna speciosa Korth, has opioid-like effects, and has been used for the treatment of chronic pain and amelioration of opioid-withdrawal symptoms. Salvia divinorum is a hallucinogen with unique pharmacology that has therapeutic potential but has been banned in many states due to concerns regarding its psychiatric effects. Methoxetamine has recently become available via the Internet and is marked as "legal ketamine." Moreover, the piperazine derivatives, a class of amphetamine-like compounds that includes BZP and TMFPP, are making a resurgence as "legal Ecstasy." These psychoactives are available via the Internet, frequently legal, and often perceived as safe by the public. Unfortunately, these drugs often have adverse effects, which range from minimal to life-threatening. Health care providers must be familiar with these important new classes of drugs. This paper discusses the background, pharmacology, clinical effects, detection, and management of synthetic cannabinoid, synthetic cathinone, methoxetamine, and piperazine exposures.


Subject(s)
Alkaloids/toxicity , Cannabinoids/toxicity , Cyclohexanones/toxicity , Cyclohexylamines/toxicity , Mitragyna/toxicity , Piperazines/toxicity , Psychotropic Drugs/toxicity , Salvia/toxicity , Alkaloids/analysis , Alkaloids/pharmacology , Alkaloids/therapeutic use , Cannabinoids/analysis , Cannabinoids/pharmacology , Cannabinoids/therapeutic use , Cyclohexanones/analysis , Cyclohexanones/pharmacology , Cyclohexanones/therapeutic use , Cyclohexylamines/analysis , Cyclohexylamines/pharmacology , Cyclohexylamines/therapeutic use , Humans , Piperazines/analysis , Piperazines/pharmacology , Piperazines/therapeutic use , Psychotropic Drugs/analysis , Psychotropic Drugs/pharmacology , Psychotropic Drugs/therapeutic use
18.
Eur J Clin Pharmacol ; 68(5): 853-6, 2012 May.
Article in English | MEDLINE | ID: mdl-22205276

ABSTRACT

PURPOSE: Long-term regular use of ketamine has been reported to be associated with severe symptomatic urinary tract problems. Methoxetamine, an arylcyclohexylamine derivative of ketamine, is marketed as a "bladder safe" derivative of ketamine, and no cases of acute toxicity following analytically confirmed methoxetamine use have been reported to date. We report here a case series of three individuals with acute toxicity related to the analytically confirmed use of methoxetamine. CASE SERIES: Three patients aged between 28 and 42 years presented to the Emergency Department (ED) on unrelated occasions having used methoxetamine. Clinical features were suggestive of a "dissociative/catatonic" state similar to that seen with ketamine; in addition, they had clinical features of acute sympathomimetic toxicity with significant tachycardia and hypertension. All were managed with low-dose benzodiazepines and discharged home once their symptoms/signs had settled. TOXICOLOGICAL SCREENING: Serum collected at the time of presentation to the ED was analysed qualitatively and quantitatively by gas chromatography-mass spectrometry. Serum concentrations ranged from 0.09 to 0.2 mg/L; in addition, detectable levels of 6-APB/5-APB were found in one of the patients. CONCLUSIONS: These three analytically confirmed cases demonstrate that acute methoxetamine-related toxicity is associated with both "dissociative" and "sympathomimetic" clinical features. The information from these three cases is useful to clinical pharmacologists, not only in managing individuals with acute methoxetamine toxicity but also in advising the appropriate legislative authorities on the risk of acute harm related to methoxetamine use. Further work is needed to determine whether methoxetamine is more "bladder friendly" than ketamine, as has been suggested by those marketing methoxetamine.


Subject(s)
Cyclohexanones/toxicity , Cyclohexylamines/toxicity , Illicit Drugs/toxicity , Neurotoxicity Syndromes/physiopathology , Administration, Inhalation , Administration, Oral , Adult , Akathisia, Drug-Induced/etiology , Anticonvulsants/administration & dosage , Anticonvulsants/therapeutic use , Catatonia/etiology , Confusion/etiology , Cyclohexanones/administration & dosage , Cyclohexanones/blood , Cyclohexylamines/administration & dosage , Cyclohexylamines/blood , Emergency Treatment , Hallucinations/etiology , Humans , Hypertension/etiology , Hypnotics and Sedatives/administration & dosage , Hypnotics and Sedatives/therapeutic use , Illicit Drugs/blood , Male , Neurotoxicity Syndromes/drug therapy , Neurotoxicity Syndromes/therapy , Seizures, Febrile/etiology , Tachycardia/etiology , Treatment Outcome
19.
Pharmacol Rep ; 63(1): 120-9, 2011.
Article in English | MEDLINE | ID: mdl-21441619

ABSTRACT

Previous studies of the propranolol monoterpene derivative (-)-4-[2-hydroxy-3-(N-isopropylamino)-propoxyimino]-cis-carane hydrochloride (KP-23) and its diastereoisomers, KP-23R and KP-23S, demonstrated different effects on the cyclic AMP generating system as well as anti-inflammatory, analgesic, antihistaminic and antioxidant activity. The present study examined the influence of KP-23 and its diastereoisomers KP-23R and KP-23S on the skin-irritating activity and the mucous membrane-irritating activity as well as their influence on a late-type contact allergy in the in vivo tests. The hydroxyl radical scavenging potential of the three analogues was evaluated using their ability to inhibit Fe(II)/H2O2-induced oxidative degradation of 2-deoxyribose (2-DR) in the in vitro tests. The results obtained indicated that the hydroxyamine carane derivative did not evoke irritative changes and did not induce a late-type contact allergy in the guinea-pig. Diastereoisomers of KP-23 exhibit antioxidant properties in a dose-dependent manner and protected against OH-radicals generated from the Fenton reaction.


Subject(s)
Antioxidants/pharmacology , Cyclic AMP/metabolism , Cyclohexylamines/pharmacology , Free Radical Scavengers/pharmacology , Animals , Antioxidants/chemistry , Antioxidants/toxicity , Bicyclic Monoterpenes , Cyclohexylamines/chemistry , Cyclohexylamines/toxicity , Deoxyribose/metabolism , Dermatitis, Allergic Contact/etiology , Dose-Response Relationship, Drug , Free Radical Scavengers/chemistry , Free Radical Scavengers/toxicity , Guinea Pigs , Male , Mucous Membrane/drug effects , Mucous Membrane/metabolism , Rabbits , Skin Irritancy Tests , Stereoisomerism , Toxicity Tests/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...